Therapeutic strategies in epithelial ovarian cancer

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Kim, Ayako ^a,b   Ueda, Yutaka ^a   Naka, Tetsuji ^b   Enomoto, Takayuki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

bevacizumab; clear cell carcinoma; conventional treatment; novel treatment; ovarian cancer; PARP inhibitor; Review

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; OLAPARIB; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; TOPOTECAN; TRABECTEDIN; BRIDGED COMPOUND; TAXANE; TAXOID;

ABDOMINAL HYSTERECTOMY; ADVANCED CANCER; ANEMIA; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CLEAR CELL CARCINOMA; COMPARATIVE STUDY; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; DNA STRAND BREAKAGE; DRUG HALF LIFE; EPITHELIAL OVARY CANCER; FOLLOW UP; HAIR LOSS; HUMAN; HYPERSENSITIVITY REACTION; LYMPHADENECTOMY; MOLECULARLY TARGETED THERAPY; NEUROTOXICITY; NEUTROPENIA; OMENTECTOMY; OVARY ADENOCARCINOMA; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REVIEW; SALPINGOOOPHORECTOMY; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; CLASSIFICATION; DISEASE FREE SURVIVAL; DRUG RESISTANCE; FEMALE; MULTIMODALITY CANCER THERAPY; NEOPLASM; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS;

BRIDGED COMPOUNDS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PLATINUM; PROGNOSIS; TAXOIDS;

EID: 84856802424     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-1422330607     Document Type: Review

References (44)

1. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Kurman RJ Shih Ie M, Am J Surg Pathol 2010 34 433 443 10.1097/PAS.0b013e3181cf3d79 20154587
2. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Rubin SC Randall TC Armstrong KA Chi DS, Hoskins WJ,, Obstet Gynecol 1999 93 21 24 10.1016/S0029-7844(98)00334-2 9916949
3. Ovarian cancer. Hennessy BT Coleman RL Markman M,, Lancet 2009 374 1371 82 10.1016/S0140-6736(09)61338-6 19793610
4. Ovarian tumorigenesis: a proposed 1 model based on orphological and molecular genetic analysis. Shih Ie M Kurman RJ, Am J Pathol 2004 164 1511 1518 10.1016/S0002-9440(10)63708-X 15111296 (Pubitemid 38529752)
5. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Kurman RJ Visvanathan K Roden R Wu TC, Shih Ie M,, Am J Obstet Gynecol 2008 198 351 356 10.1016/j.ajog.2008.01.005 18395030 (Pubitemid 351451941)
6. Ovarian cancer. Cho KR Shih Ie M, Annu Rev Pathol 2009 4 287 313 10.1146/annurev.pathol.4.110807.092246 18842102
7. The cell of origin of ovarian epithelial tumours. Dubeau L, Lancet Oncol 2008 9 1191 7. Review 10.1016/S1470-2045(08)70308-5 19038766
8. International Collaborative Ovarian Neoplasm trial and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. Trimbos JB Parmar M Vergote I,,, et al. J Natl Cancer Inst 2003 95 105 112 12529343 (Pubitemid 36196730)
9. The Role of Surgery in the Management of Epithelial Ovarian Cancer: Role of Surgery. Ramirez I Chon HS Apte SM,, http://www.medscape.com/viewarticle/ 738258-3
10. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. Vergote I Trope CG Amant F,,, et al. N Engl J Med 2010 363 943 953 10.1056/NEJMoa0908806 20818904
11. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. Markman M Reichman B Hakes T,,, et al. J Clin Oncol 1991 9 1801 1805 1919630
12. Treatment of recurrent epithelial ovarian cancer. Pisano C Bruni GS Facchini G Marchetti C, Pignata S,, Ther Clin Risk Manag 2009 5 421 426 19753136
13. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Parmar MK Ledermann JA Colombo N,,, et al. Lancet 2003 361 2099 2106 12826431
14. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. Monk BJ Herzog TJ Kaye SB,,, et al. J Clin Oncol 2010 28 3107 3114 10.1200/JCO.2009.25.4037 20516432
15. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Vaage J Donovan D Mayhew E Abra R, Huang A,, Cancer 1993 72 3671 3675 10.1002/1097-0142(19931215)72:12<3671: :AID-CNCR2820721219>3.0.CO;2-U 8252484 (Pubitemid 24000603)
16. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. Pujade-Lauraine E Wagner U Aavall-Lundqvist E,,, et al. J Clin Oncol 2010 28 3323 3329 10.1200/JCO.2009.25.7519 20498395
17. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Sugiyama T Kamura T Kigawa J,,, et al. Cancer 2000 88 2584 2589 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5 10861437 (Pubitemid 30331967)
18. Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? T Enomoto CK Yamasaki M Sugita N Otsuki Y, Ikegami H Matsuzaki N, Yamada T Wakimoto A, Murata Y,, Proc Am Soc Clin Oncol 2003 22 477s (abstr#1797)
19. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Takakura S Takano M Takahashi F,,, et al. Int J Gynecol Cancer 2010 20 240 247 10.1111/IGC.0b013e3181cafb47 20169667
20. Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients. Yoshino K Enomoto T, Fujita M Ueda Y, Kimura T Kobayashi E, Tsutsui T Kimura T, Int J Clin Oncol 2011
21. Chemotherapy of advanced ovarian cancer. McGuire WP Ozols RF, Semin Oncol 1998 25 340 348 9633846 (Pubitemid 28272608)
22. Randomized intergroup trial of cisplatin paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. Piccart MJ Bertelsen K James K,,, et al. J Natl Cancer Inst 2000 92 699 708 10.1093/jnci/92.9.699 10793106 (Pubitemid 30365530)
23. Phase III randomized study of 1 cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. Muggia FM Braly PS Brady MF,,, et al. J Clin Oncol 2000 18 106 115 10623700 (Pubitemid 30036343)
24. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. Armstrong DK Bundy B Wenzel L,,, et al. N Engl J Med 2006 354 34 43 10.1056/NEJMoa052985 16394300 (Pubitemid 43048949)
25. Chemotherapy in epithelial ovarian cancer. Pignata S Cannella L, Leopardo D Pisano C, Bruni GS Facchini G, Cancer Lett 2011 303 73 83 10.1016/j.canlet.2011.01.026 21353386
26. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. Chan S Friedrichs K Noel D,,, et al. J Clin Oncol 1999 17 2341 2354 10561296 (Pubitemid 29368232)
27. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. Jones SE Erban J Overmoyer B,,, et al. J Clin Oncol 2005 23 5542 5551 10.1200/JCO.2005.02.027 16110015
28. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer-an updated overview. Kaye SB Piccart M Aapro M Francis P, Kavanagh J,, Eur J Cancer 1997 33 2167 2170 10.1016/S0959-8049(97)00363-8 9470802
29. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Rose PG Blessing JA Ball HG,,, et al. Gynecol Oncol 2003 88 130 135 10.1016/S0090-8258(02)00091-4 12586591 (Pubitemid 36263370)
30. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Vasey PA Atkinson R Coleman R,,, et al. Br J Cancer 2001 84 170 178 10.1054/bjoc.2000.1572 11161372 (Pubitemid 32113441)
31. Phase III randomized trial of docetaxel carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. Vasey PA Jayson GC Gordon A,,, et al. J Natl Cancer Inst 2004 96 1682 1691 10.1093/jnci/djh323 15547181 (Pubitemid 39585637)
32. Overcoming Platinum Resistance in Ovarian Carcinoma. Matsuo K Lin YG, Roman LD Sood AK, Expert Opin Investig Drugs 2010 19 1339 1354 10.1517/13543784.2010.515585 20815774
33. VEGF-targeted therapy: mechanisms of anti-tumour activity. Ellis LM Hicklin DJ, Nat Rev Cancer 2008 8 579 591 10.1038/nrc2403 18596824
34. Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma. Raspollini MR Castiglione F Garbini F,,, et al. Int J Surg Pathol 2005 13 135 142 10.1177/106689690501300202 15864375 (Pubitemid 40617540)
35. Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. Burger RA Brady MF Bookman MA Fleming GF, Monk BJ Huang H, Mannel RS Homesley HD, Fowler J Greer BE, Boente M Birrer MJ, Liang SX,, N Engl J Med 2011 365 2473 83 10.1056/NEJMoa1104390 22204724
36. ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. Perren TJ Swart AM, Pfisterer J Ledermann JA, Pujade-Lauraine E Kristensen G, Carey MS Beale P, Cervantes A Kurzeder C, du Bois A Sehouli J, Kimmig R Stähle A, Collinson F Essapen S, Gourley C Lortholary A, Selle F Mirza MR, Leminen A Plante M, Stark D Qian W, Parmar MK Oza AM, N Engl J Med 2011 365 2484 96 10.1056/NEJMoa1103799 22204725
37. Aghajanian C Finkler NJ, Rutherford T Smith DA, Yi J Parmar H, Nycum LR Sovak MA, J Clin Oncol 2011 29 Memorial Sloan-Kettering Cancer Center, New York, NY; Florida Hospital Gynecologic Oncology, Florida Hospital Cancer Institute, Orlando, FL; Yale University School of Medicine, New Haven, CT; Northwest Cancer Specialists, Vancouver, WA; Genentech Inc., South San Francisco, CA; Forsyth Regional Cancer Center, Winston-Salem, NC. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). (suppl; abstr LBA5007)
38. PARP inhibition: PARP1 and beyond. Rouleau M Patel A Hendzel MJ Kaufmann SH, Poirier GG,, Nat Rev Cancer 2010 10 293 301 10.1038/nrc2812 20200537
39. Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. Itamochi H, World J Biol Chem 2010 1 209 220 10.4331/wjbc.v1.i7.209 21537476
40. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. King MC Marks JH Mandell JB,, Science 2003 302 643 646 10.1126/science.1088759 14576434 (Pubitemid 37310920)
41. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. Press JZ De Luca A Boyd N,,, et al. BMC Cancer 2008 8 17 10.1186/1471-2407-8-17 18208621
42. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Helleday T, Mol Oncol 2011 5 387 93 10.1016/j.molonc.2011.07.001 21821475
43. Inhibition of poly(ADP-ribose) polymerase 1 in tumors from BRCA mutation carriers. Fong PC Boss DS Yap TA,,, et al. N Engl J Med 2009 361 123 134 10.1056/NEJMoa0900212 19553641
44. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. Fong PC Yap TA, Boss DS,, et al. J Clin Oncol 2010 28 2512 2519 10.1200/JCO.2009.26.9589 20406929